Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908252 · ClinicalTrials.gov registry record · Phase 4
MAPS PrEP Van Study
A Phase 4 study of HIV Infection, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06908252: Recruiting Phase 4 study of HIV Infection, sponsored by Duke University.
NCT06908252 is a Phase 4 study of HIV Infection that is actively recruiting participants, run by Duke University. The registered enrollment target is 20 participants, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06908252, a Phase 4 study of HIV Infection, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting HIV.
Primary Outcome
Number of participants utilizing medical mobile unit during study duration who are eligible for PrEP
Conditions Studied
Interventions
- DRUG Pre-Exposure Prophylaxis (PrEP)
Study Locations (1)
North Carolina
- Duke Department of Population Health Sciences - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
What NCT06908252 shows while recruiting
NCT06908252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (92% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Pre-Exposure Prophylaxis (PrEP) is the first listed.
NCT06908252 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06908252 about?
NCT06908252 is a clinical study titled "MAPS PrEP Van Study". For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting HIV.
What is the current status of trial NCT06908252?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-09-17. Estimated completion is 2026-07-31.
What conditions does trial NCT06908252 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT06908252?
The interventions under investigation include: Pre-Exposure Prophylaxis (PrEP) (DRUG).
Who is sponsoring clinical trial NCT06908252?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908252 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06908252's enrollment target sits among peer trials
20 60th of 73 higher than 11 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
COMPLETED · Phase 4
-
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
COMPLETED · Phase 4
-
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
COMPLETED · Phase 4
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
COMPLETED · Phase 4
-
Safety and Efficacy Study of Switching From Epzicom to Truvada
COMPLETED · Phase 4
-
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI